Perrigo fiscal 1996 sales grow 9%, fueled by OTCs, nutritionals.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO FY 1996 SALES INCREASE 9% BUOYED BY GROWING NUTRITIONALS BUSINESS and rising OTC drug sales, the private-label manufacturer reported Aug. 14. Sales for the fiscal year ended June 30 rose to $778.1 mil., up from $717.1 mil. in FY 1995. However, net profits for fiscal 1996 slumped, falling 10.3% to $39.8 mil
You may also be interested in...
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.